Chestnut Ridge, NY, United States of America

Edmund Graziani

This inventor holds 16 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Wyeth, Pfizer Corporation, Wyeth Holdings Corporation. Active years: 2006-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Edmund Graziani. Retrieved from https://idiyas.com/inventor/edmund-graziani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 4)

% Patents Active = 37.5

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 105(Granted Patents)

Location History:

Ridgewood, NJ (US) (2006 - 2009)
Chestnut Ridge, NY (US) (2007 - 2021)

Company Filing History:

Wyeth Holdings Corporation

patents

Years Active: 2006-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11147852 - Engineered antibody constant regions for site-specific conjugation and methods and uses therefor (2021-10-19),

2. 10689458 - Site specific HER2 antibody drug conjugates (2020-06-23),

3. 9249186 - Cytotoxic peptides and antibody drug conjugates thereof (2016-02-02),

4. 9138486 - Cytotoxic peptides and antibody drug conjugates thereof (2015-09-22),

5. 8828401 - Cytotoxic peptides and antibody drug conjugates thereof (2014-09-09),

6. 8030325 - Biosynthetic gene cluster for the production of a complex polyketide (2011-10-04),

7. 7795252 - Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders (2010-09-14),

8. 7745457 - Meridamycin analogues for the treatment of neurodegenerative disorders (2010-06-29),

9. 7560457 - Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders (2009-07-14),

10. 7507752 - Biosynthetic gene cluster for the production of a complex polyketide (2009-03-24),

11. 7476678 - Rapamycin derivatives and the uses thereof in the treatment of neurological disorders (2009-01-13),

12. 7470682 - Rapamycin analogues and the uses thereof in the treatment of neurological disorders (2008-12-30),

13. 7276498 - Rapamycin analogues and uses thereof in the treatment of neurological disorders (2007-10-02),

14. 7273874 - Rapamycin derivatives and the uses thereof in the treatment of neurological disorders (2007-09-25),

15. 7247650 - Macrolides and methods for producing same (2007-07-24),

Title: Edmund Graziani: Innovator in Antibody Engineering

Introduction

Edmund Graziani is a notable inventor based in Chestnut Ridge, NY (US), recognized for his contributions to the field of antibody engineering. With a total of 16 patents to his name, Graziani has made significant advancements in the development of engineered antibodies and their applications in therapeutics.

Latest Patents

Graziani's latest patents include innovative technologies such as engineered antibody constant regions for site-specific conjugation. This invention focuses on antibodies and antigen-binding portions that are engineered to introduce amino acids for site-specific conjugation. It encompasses engineered antibody constant region polypeptides and antibodies that include these polypeptides. Additionally, it relates to Fc fusion proteins that comprise an engineered Fc region, along with methods and uses for producing antibody-drug conjugate therapeutics. Another significant patent involves site-specific HER2 antibody drug conjugates, providing methods for preparing and utilizing these conjugates effectively.

Career Highlights

Throughout his career, Graziani has worked with prominent companies in the pharmaceutical industry, including Wyeth and Pfizer Corporation. His work has contributed to the advancement of therapeutic solutions that leverage the power of engineered antibodies.

Collaborations

Graziani has collaborated with notable professionals in his field, including Kevin Pong and Jerauld S Skotnicki. These collaborations have further enhanced the impact of his innovations in antibody engineering.

Conclusion

Edmund Graziani's work in antibody engineering has paved the way for new therapeutic approaches, showcasing his expertise and dedication to innovation. His contributions continue to influence the field and hold promise for future advancements in medical science.

Profile summary based on public USPTO records.